Current Market Context and Price Movement
On 25 November 2025, Zenotech Laboratories' stock price touched Rs.47.5, the lowest level recorded in the past year. This decline comes after two consecutive days of price falls, although the stock showed a modest gain today, moving in line with its sector's performance. Despite this slight recovery, the share price remains below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating sustained downward momentum over multiple timeframes.
In contrast, the broader market has exhibited positive trends. The Sensex opened 108.22 points higher and was trading at 85,013.69, reflecting a 0.13% gain. The benchmark index is also nearing its 52-week high of 85,801.70, currently just 0.93% away. Mid-cap stocks have led the market rally, with the BSE Mid Cap index gaining 0.24% today. This divergence highlights the relative underperformance of Zenotech Laboratories within the pharmaceuticals and biotechnology sector.
While markets shift, this one's charging ahead! This Micro Cap from Aquaculture shows the strongest momentum signals in current conditions. Don't miss out on this ride!
- - Strongest current momentum
- - Market-cycle outperformer
- - Aquaculture sector strength
Performance Overview and Financial Indicators
Over the last twelve months, Zenotech Laboratories has recorded a return of -35.44%, a stark contrast to the Sensex's 6.10% gain during the same period. The stock's 52-week high was Rs.78, underscoring the extent of the decline to the current low. This performance reflects challenges in both short-term and long-term horizons, with the company also underperforming the BSE500 index over one year, three years, and three months.
Financial results from the recent quarter reveal a net loss after tax (PAT) of Rs.-0.84 crore, representing a fall of 180.6% compared to the previous four-quarter average. The profit before depreciation, interest, and taxes (PBDIT) stood at Rs.2.28 crore, the lowest recorded in recent quarters. Operating profit as a percentage of net sales also reached a low of 20.30%, indicating pressure on profitability margins.
Despite these figures, the company maintains a return on equity (ROE) of 2.8%, which is modest relative to its valuation metrics. The stock trades at a price-to-book value of 3.1, suggesting a premium compared to historical averages of its peers. Over the past year, profits have declined by 54.1%, further reflecting the financial strain experienced by the company.
Balance Sheet Strength and Operational Metrics
Zenotech Laboratories exhibits certain strengths in its financial structure. The company reports a high management efficiency with an ROE of 16.36%, indicating effective utilisation of shareholder funds in some operational aspects. Additionally, the debt to EBITDA ratio is low at 0.44 times, signalling a strong capacity to service debt obligations without significant strain.
Operating profit has shown a compound annual growth rate of 33.32%, suggesting that despite recent setbacks, the company has demonstrated healthy growth in its core earnings over a longer timeframe. The majority shareholding remains with promoters, providing a stable ownership structure.
Zenotech Laboratories or something better? Our SwitchER feature analyzes this micro-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Sector and Market Comparison
Within the Pharmaceuticals & Biotechnology sector, Zenotech Laboratories' current valuation and price trends contrast with broader market movements. While the Sensex and mid-cap indices have shown resilience and upward momentum, Zenotech's share price remains subdued. The stock's position below all major moving averages highlights a cautious market stance towards the company relative to its sector peers.
Investors observing the sector will note that the company's recent financial results and price behaviour reflect a period of adjustment. The stock's premium valuation relative to peers, despite recent profit declines, suggests that market participants are weighing various factors in their assessment.
Summary of Key Price and Financial Data
Zenotech Laboratories' stock price today: Rs.47.5 (52-week low)
52-week high: Rs.78
One-year return: -35.44%
Sensex one-year return: 6.10%
Latest quarterly PAT: Rs.-0.84 crore
Latest quarterly PBDIT: Rs.2.28 crore
Operating profit to net sales (quarterly): 20.30%
ROE: 2.8% (overall), 16.36% (management efficiency)
Debt to EBITDA ratio: 0.44 times
Price to book value: 3.1
These figures provide a comprehensive snapshot of the company's recent financial and market position as it navigates a challenging environment within the pharmaceuticals and biotechnology sector.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
